Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 9/23/2012 |
| Start Date: | July 2012 |
| End Date: | March 2016 |
| Contact: | For participation information at a USA site use a phone number below. For site information outside the USA please email: |
| Email: | Clinical.Trials@bms.com |
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
The purpose of this trial is to determine whether Ipilimumab will prolong survival when
compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
Inclusion Criteria:
- Non-Squamous, Non-Small Cell Lung Cancer
- Recurrent/Stage IV Non-small cell lung cancer (NSCLC)
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
- Not progressing after 4 cycles of a platinum-based first line chemotherapy
Exclusion Criteria:
- Brain Metastases (unless stable)
- Autoimmune Diseases
We found this trial at
12
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials